U.S. markets close in 6 hours 2 minutes
  • S&P 500

    3,748.68
    -70.15 (-1.84%)
     
  • Dow 30

    30,473.64
    -555.67 (-1.79%)
     
  • Nasdaq

    10,903.36
    -274.53 (-2.46%)
     
  • Russell 2000

    1,686.98
    -32.39 (-1.88%)
     
  • Crude Oil

    108.28
    -1.50 (-1.37%)
     
  • Gold

    1,818.50
    +1.00 (+0.06%)
     
  • Silver

    20.48
    -0.26 (-1.27%)
     
  • EUR/USD

    1.0413
    -0.0030 (-0.29%)
     
  • 10-Yr Bond

    3.0170
    -0.0760 (-2.46%)
     
  • GBP/USD

    1.2148
    +0.0026 (+0.22%)
     
  • USD/JPY

    135.9060
    -0.6390 (-0.47%)
     
  • BTC-USD

    18,897.87
    -1,183.00 (-5.89%)
     
  • CMC Crypto 200

    404.59
    -26.88 (-6.23%)
     
  • FTSE 100

    7,129.19
    -183.13 (-2.50%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

Vapotherm to Participate in the William Blair 42nd Annual Growth Stock Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

EXETER, N.H., June 01, 2022--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022.

Vapotherm is scheduled to present at 1:40 pm Eastern Time. The presentation will be accessible via a live webcast at https://wsw.com/webcast/blair66/vapo/1945188.

A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.

About Vapotherm

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 3.5 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.

Vapotherm high velocity therapy is mask-free non-invasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

Website Information

Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission ("SEC") filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005224/en/

Contacts

Investor Relations:
Mark Klausner or Mike Vallie, Westwicke, an ICR Company, ir@vtherm.com, +1 (603) 658-0011